Key facts
- It has raised $5.5M; the latest was Grant ($5.0M) in Sep 2025.
- Notable investors include Bpifrance, Enseignement Supérieur et de la Recherche, French Ministry of Education Nationale, Gold Track, Health Technology Holding — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Lys Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lys Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lys Therapeutics
Developer of biotherapies designed to treat patients suffering from neurovascular or neurodegenerative disorders. The company's drugs are based on the monoclonal antibody, one protease called tissue plasminogen activator (tPA) that triggers off-target toxicity through hyperactivation of both vascular and neuronal NMDA receptors (NMDAr), enabling healthcare providers to counteract neuroinflammation to tackle neurodegeneration.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2021
- Employees
- 14
- Website
- lystherapeutics.com/
- Ownership
- Privately Held (backing)
Lys Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lys Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lys Therapeutics in its N-PORT filings yet. We sweep new filings monthly.